1	Binding and neutralizing IgG responses to SARS-CoV-2 after natural infection or
2	vaccination
3	Kaylan M. Olds, MS, ¹ Devon P. Humphreys, MA, ¹ Kathleen M. Gavin, PhD, ^{1,2} Anne L. Wyllie,
4	PhD ³ and Timothy A. Bauer, PhD ^{1,2*}
5	¹ Everly Health, Inc., 823 Congress Ave, STE 1200, Austin TX 78701
6	² University of Colorado Anschutz Medical Campus, Aurora, CO 80045
7	³ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New
8	Haven, CT 06510
9	*Corresponding Author
10	
11	Address for correspondence:
12	Timothy Bauer, PhD, Everly Health, Inc., 823 Congress Ave., Suite 1200, Austin, TX 78701;
13	phone: 303-503-5713; email: tbauer@everlyhealth.com
14	
15	Keywords:
16	COVID-19; humans; adults; immunity; seroprevalence; antibody durability; dried blood spot
17	
18	
19	

20 Abstract (227 words)

21 <u>Background</u>: Whether vaccination or natural infection provides greater benefit regarding the

22 development of sustained immunity against SARS-CoV-2 remains unknown. Therefore, the aim

- 23 of this study was to provide a direct comparison of IgG durability and neutralizing antibody
- 24 (NAb) levels in vaccinated and unvaccinated adults.

25 <u>Methods</u>: This was a prospective, cross-sectional study of antibody durability in 1087 individuals

26 with a median (IQR) age of 42 (35, 52) years who were unvaccinated and previously infected

27 with SARS-CoV-2 (Arm 1, n=351) or vaccinated against the virus (Arm 2, n=737). Participants

28 self-reported vaccination and infection history and provided self-collected serology samples

29 using mailed collection kits.

30 <u>Results</u>: Anti-S1 IgG seroprevalence was 15.6% higher in vaccinated versus unvaccinated,

31 previously-infected individuals across intervals ranging from 1 to 12 months and antibody

32 survival was sustained near 100% through 12 months in the vaccinated group. NAb titers at 50%

inhibition were significantly greater in vaccinated individuals with values that averaged 893.0

34 units higher than those observed in the unvaccinated, naturally infected group.

35 <u>Conclusions</u>: These findings suggest that vaccination as opposed to natural infection alone

36 provides significant advantages in terms of sustained and effective (neutralizing) immunity

against prior variants of SARS-CoV-2. Future efforts to characterize SARS-CoV-2 immune

38 responses should address hybrid immunity, booster status and formulation, and protection

against (sub)variants of Omicron and future lineages, as well as weigh the potential impact of

40 other immune system mechanisms.

41

43 Introduction

44 Throughout the course of the Coronavirus Disease 2019 (COVID-19) pandemic, the widespread 45 adoption of vaccination has been promoted for its potential to significantly curtail health and 46 economic burdens related to the spread of SARS-CoV-2, and ultimately, key to bringing the 47 pandemic to an end (1, 2). In less than a year from the World Health Organization (WHO) 48 declaring the pandemic, following an unprecedented development effort, vaccines were available 49 to most adults in western societies. However, vaccination campaigns were met with varying 50 degrees of hesitancy in portions of the population (3-5). In the intervening months, researchers 51 documented Immunoglobulin G (IgG) seroconversion and fluctuating levels of sustained 52 immunity resulting from natural infection and/or vaccination (6-15), and established a positive 53 relationship between anti-spike antibodies and clinical protection from SARS-CoV-2 (16-18). 54 55 However, the current literature does not provide a clear difference in antibody profiles acquired 56 through vaccination and natural infection. This distinction is of renewed importance at a time 57 when nearly 60% of the United States (US) population (including 75% of US children) are 58 reported to show serological evidence of community exposure (19) and the sense of urgency 59 related to vaccination has waned. Despite a growing body of literature, availability of data 60 directly comparing antibody responses following vaccination versus natural infection is limited. 61 Prospective evaluations tend to be limited in sample size (12, 14, 20-22), have short serological 62 monitoring periods, (9, 20, 22) or analyses were completed retrospectively (23, 24). Many studies 63 utilize populations of healthcare workers who may encounter infectious agents – including 64 SARS-CoV-2 – more frequently than other members of the community, limiting generalizability 65 of results due to potential repeated exposures and subclinical infections (9, 12, 20, 25). Several

66 quality studies have evaluated the effectiveness of vaccination- and/or infection-acquired 67 immunity over time, but have lacked a serological component (24-26). Therefore, in the current 68 study, we aimed to provide a direct comparison of IgG durability and neutralizing antibody 69 (NAb) levels in vaccinated and unvaccinated individuals in a prospective US sample. This work 70 presents the largest such comparison in a prospectively-collected, population-wide sample to 71 date. 72 73 **Methods** 74 *Ethics approval and consent to participate* 75 This protocol was approved by WCG IRB (IRB registration #20210763). All participants 76 provided written informed consent prior to enrollment in the study. 77 78 Study design 79 This was a prospective, cross-sectional study of antibody durability in individuals who were 80 previously infected with SARS-CoV-2 (Arm 1) or vaccinated against the virus (Arm 2). The 81 study utilized electronic questionnaires and self-collected dried blood spot (DBS) samples to 82 gather data remotely from participants within the US. Upon enrollment, participants answered 83 questions about COVID-19 diagnosis and vaccination history, symptom and treatment 84 information, and other relevant medical history such as comorbid conditions and medication use. 85 Participants received a COVID-19 Antibody Home Collection Kit (Everlywell, Inc., Austin, TX) 86 to provide samples for qualitative IgG detection. Baseline data were captured to complete the 87 primary analysis of comparative IgG durability between study arms. In addition, Arm 2

00		· ·	1 1 4	1 ' C 11	10 0
88	participants repeated	auestionnaires an	a serology test	s during a follow	v-up period for up to 9

89 months, facilitating a secondary survival analysis of vaccine-acquired IgG.

90

91 Participant eligibility and enrollment

92 Participants were enrolled in the study between March and November 2021. Inclusion criteria for

93 Arm 1 included prior infection with SARS-CoV-2 (evidenced by a positive diagnostic test) and

94 unvaccinated status. Eligibility for Arm 2 required receipt of at least one dose of a SARS-CoV-2

vaccine. All participants were required to be age 18 years or older, reside within the continental

96 US, and have access to an email account and internet service. Exclusion criteria included known

97 conditions or ongoing treatments associated with immune impairment (e.g., chemotherapy) and

98 residents of New York state. All participants provided written informed consent prior to

99 enrollment in the study, which was approved by WCG IRB (IRB study #20210763).

100

101 *Serology Testing*

102 DBS samples were self-collected at baseline and follow-up timepoints for serology testing using

103 the Anti-SARS-CoV-2 ELISA Assay (EUROIMMUN, Germany). A subset of samples was

104 subjected to secondary testing using the NAB-Sure[™] SARS-CoV-2 Neutralizing Antibody Test

105 (SpearBio, Inc, Woburn, MA).

106

107 Study Endpoints

108 The primary endpoint was the expected difference in S1-binding IgG seropositivity between Arm

- 109 1 (unvaccinated, naturally infected individuals) and Arm 2 (vaccinated individuals) over
- time. The secondary endpoints included: (1) the difference in expected NAb titer between Arm 1

and Arm 2 over time, and (2) S1-binding IgG and NAb survival percentages at 4 and 12 months
since last exposure to a vaccine product in Arm 2.

113

114 Statistical Analysis

analysis.

Multiple linear regression was used to evaluate the effect size and significance of each study arm (vaccination vs natural infection) on estimated seropositivity over time (binned as the number of months since last vaccine dose or infection). Estimates per study arm per time interval that included fewer than 3 serology values were considered under sampled and dropped prior to

120

119

121 Additionally, a discrete-time analysis was conducted using independent z-tests of proportions at 122 1, 3, 6, 9, and 12 months to evaluate differences in seropositivity between Arms 1 and 2. P-123 values are reported and interpretable using a Bonferroni-adjusted value of 0.005. To further 124 evaluate S1-binding IgG durability associated with vaccination, survival analysis was performed 125 using the Kaplan-Meier method. Percent survival at 4 and 12 months is reported with 95% 126 confidence intervals. This analysis was conducted in two ways, reflecting (1) time from the most 127 recent vaccination dose (i.e., a booster dose reset the interval clock), and (2) time from the initial 128 vaccination dose. For the NAb analysis, as above, the time variable was binned as the number of 129 months since the last vaccine dose or infection. Quantitative NAb titer was similarly evaluated 130 over time, stratified by study arm.

131

132 **Results**

133 S1-binding IgG Cross-Sectional Analysis

- 134 A total of 1,087 participants enrolled in the study and completed all required baseline
- assessments for inclusion in the analysis: 351 were assigned to Arm 1 and 737 were assigned to
- 136 Arm 2 at baseline. Over three quarters of participants included in the cross-sectional analysis
- 137 were female, and the median (IQR) age was 42 (35, 52) years. Over two thirds of vaccinated
- 138 participants reported no previous SARS-CoV-2 infection prior to entering the study. Baseline
- 139 participant characteristics are summarized in Table 1.
- 140

Characteristic	Overall	Arm 1	Arm 2
Characteristic	N = 1088	N = 351	N = 737
Sex			
Female	831 (76%)	258 (74%)	573 (78%)
Male	255 (23%)	93 (26%)	162 (22%)
Unknown	2 (0.2%)	0 (0%)	2 (0.3%)
Age			
Median (IQR)	42 (35, 52)	43 (34, 54)	42 (35, 51)
Unknown	2 (0.2%)	0 (0%)	2 (0.3%)
COVID Diagnostic History			
Known Infection	566 (52%)	351 (100%)	215 (29%)
No Known Infection	508 (47%)	0 (0%)	508 (69%)
Unknown/NA	14 (1.3%)	0 (0%)	14 (1.9%)
Vaccine Product			
Ad26.COV2.s (Johnson &	56 (5.1%)	0 (0%)	56 (7.6%)
Johnson)			
BNT162b2 (Pfizer)	396 (36%)	0 (0%)	396 (54%)
mRNA-1273 (Moderna)	280 (26%)	0 (0%)	280 (38%)
NVX-CoV2373 (Novavax)	1 (<0.1%)	0 (0%)	1 (0.1%)
Not Applicable	351 (32%)	351 (100%)	0 (0%)
Unknown	4 (0.4%)	0 (0%)	4 (0.5%)

141 Table 1: Participant demographics and diagnostic test history

- 142
- 143

144 Nearly all Arm 2 participants entered the study fully vaccinated, defined as having received all

- doses in the primary series of the applicable vaccine, with only 3.7% reporting partial
- 146 vaccination (or only having received one dose of a two-dose primary vaccination regimen) at

- 147 baseline. No participants reported receiving a booster dose prior to enrollment. The difference in
- 148 time between participants' most recent confirmed exposure (positive diagnostic test date or
- vaccination date for Arm 1 or 2, respectively) and baseline serology test date ranged from 1 to 15
- 150 months (median) after dropping under-sampled time intervals (N=1,007).
- 151
- 152 Population-wide seropositivity remained high across time intervals. The seropositivity effect size
- associated with vaccination was 15.6% greater than the reference arm (Arm 1), independent of
- time since vaccination (Figure 1 and Table 2).
- 155
- 156 Table 2: Difference in seropositivity by exposure mode

Time Interval	Difference in Arm 2 (Vaccinated) versus Arm 1 (Unvaccinated/Natural Infection)	Z-score	p-value
1 month	+11.9%	-28.06	1.37×10^{-173}
3 months	+14.3%	-125.62	0.00
6 months	+15.6%	-66.93	0.00
9 months	+13.5%	-13.58	2.71×10^{-42}
12 months	+11.1%	-4.33	7.34×10^{-6}

157

158 *S1-binding IgG Longitudinal Analysis in vaccinated individuals (Arm 2)*

159 A total of 1,605 samples from 737 vaccinated individuals were available for antibody survival

analysis. Antibody survival (with 95% CI) ranged from 99.4% (99.0%-100%) at 4 months to

161 95.5% (91.7%-99.5%) at 12 months when measured in time since the last dose received, and

162 from 99.7% (99.3% - 100%) at 4 months to 98.4% (97.1%-99.7%) at 12 months when measured

- 163 from the first dose. No further loss of IgG detectability was observed beyond 12 months in either
- analysis.
- 165

166 NAb Cross-Sectional Analysis

167	One sample from each of 332 individuals was included in the sub-cohort NAb analysis,
168	including 122 Arm 1 (unvaccinated, previously infected) samples and 210 Arm 2 (vaccinated)
169	samples. The sub-cohort was predominantly female (77.1%). The median (IQR) age was 44
170	years in both Arm 1 (37, 55) and Arm 2 (37, 52).
171	
172	NAb titers at 50% inhibition (NT50) were significantly greater in Arm 2 (vaccinated) individuals
173	independent of sex and age, with values that averaged 893.0 units higher than those observed in
174	the unvaccinated group (Arm 1) ($p = 1.41 \times 10^{-5}$). When the analysis was repeated using
175	seropositive samples only (115 Arm 1 samples and 199 Arm 2 samples), the average difference
176	increased to 915.17 units higher in the vaccinated versus unvaccinated group ($p = 1.81 \times 10^{-5}$).
177	Time since last exposure (in months) also demonstrated a significant increase in NAb titer in
178	Arm 2 over Arm 1 (effect size = 319.04 , p = 1.18×10^{-8} ; Figure 2).

179

180 **Discussion**

181 This study aimed to provide the first direct comparison of IgG durability and NAb levels in 182 vaccinated and unvaccinated individuals in a large, prospective, population-wide US sample. 183 Both vaccination against COVID-19 and natural infection with SARS-CoV-2 are associated with seroconversion in most people. However, we found IgG seropositivity was significantly higher, 184 185 more consistent, and declined less rapidly in vaccinated individuals than in those who were 186 unvaccinated and previously infected with the virus. This pattern was evident one-month post-187 exposure (the earliest time interval evaluated) and persisted through 12 months post infection or 188 most recent vaccination dose. One possible explanation for the discrepancy between vaccinated

189 and naturally infected groups could be the controlled dose of target antigen provided (indirectly, 190 in many cases) through vaccination, versus the inconsistent "dose" of various viral antigens 191 acquired through natural infection. In a within-subject survival analysis, vaccine-acquired IgG 192 antibodies persisted for up to 12 months (or more) in nearly all cases. This provides within-193 subject support for strong antibody durability out to 12 months when compared to the vaccinated 194 group (Arm 2) in the cross-sectional analysis. Collectively, these analyses suggest that IgG 195 antibodies raised through vaccination are more reliably durable than those induced by a natural 196 SARS-CoV-2 infection in most individuals. In addition, vaccinated individuals demonstrated 197 higher NAb titers than unvaccinated, previously infected individuals, which prior work has 198 demonstrated as highly predictive of clinical protection against the virus (17).

199

Compared to prior research, our estimated rate of seropositivity decline in the unvaccinated 200 201 group was steeper. Alfego et al. found seropositivity decline to be approximately -0.004% per 202 day, or approximately -0.12% per month (11), while we observed a decline of -0.93% per month. 203 This may be reflective of our smaller sample size or due to an important distinction between each 204 studies' methods. Alfego et al. evaluated seropositivity from the time of a participant's first 205 recorded infection (positive diagnostic test) and did not take subsequent exposure events into 206 account, whereas in the current study, we measured seropositivity from the time of the most 207 recent confirmed infection. Nevertheless, the rate of seropositivity decline in the vaccinated 208 cohort was much lower than in the unvaccinated cohort. This holds true whether we compare this 209 rate to those estimates from Alfego et al. or to our own rate estimates for Arm 1 in the present 210 study. Collectively, this suggests that S-protein antibodies raised through vaccination are more 211 reliably durable than those induced by a natural SARS-CoV-2 infection in most individuals.

ົ	1	2
2	т	2

213	While NAb titer is a closer surrogate for immune protection, Anti-S IgG testing offers an
214	advantage in scalability as the requisite immunoassays are less burdensome in terms of time,
215	cost, complexity, and availability than functional NAb assays. Published works by Harvala et al.
216	and Lumley et al. lend support to the clinical relevance of IgG values. The former reported that
217	detection of IgG with the Euroimmun assay highly correlated with NAb titers above 1:100 in
218	convalescent blood samples (27), while the latter observed a connection between S-binding IgG
219	and protection from reinfection with earlier variants of SARS-CoV-2 in previously-infected
220	healthcare professionals followed up to 6 months (18).
221	
222	We found that vaccinated individuals showed higher NAb titers than unvaccinated individuals.
223	Given that NAb concentration correlates with protection against infection and severe disease (16,
224	17), our observations suggest that vaccine-acquired immunity may also be more protective than
225	an immune response triggered by natural infection alone. Our findings support similar
226	observations made in Congolese individuals at 2 months post vaccination (with Ad26.COV.2 or
227	BBIP-CorV) compared to 2, 3, or 6 months post natural infection (21). However, whether a
228	vaccine-induced NAb response provides an advantage over the longer term remains unclear. For
229	example, in a previous evaluation of purely vaccine-induced NAb activity in 62 healthcare
230	workers, which excluded cases of prior exposures or breakthrough infections, Decru et al. found
231	significant waning of neutralization activity 10 months after receiving a second dose of
232	BNT162b2 (12). In contrast, here we observed an apparent rise in NAb titer over time (for up to
233	12 months since last reported dose) that was driven predominantly by samples in the vaccinated
234	group. If NAb follows similar patterns as anti-S IgG, it may be that hybrid immunity provides

235	the most durable NAb response. More research is needed to clarify which approach produces the
236	longest enduring neutralization capability. Furthermore, the limitation remains that without more
237	prevailing use of a common reference standard it is difficult to determine what level of titer is
238	necessary for protection, whether that involves full immunity or simply protection from severe
239	disease. In addition, the contribution of other immune factors (e.g., IgA and mucosal immunity)
240	on overall protection should not be overlooked, especially considering those responses may
241	follow different patterns than IgG after vaccination or natural infection.
242	
243	One problem that warrants further study is the impact of symptom severity on antibody
244	responses in previously-infected individuals who become vaccinated (hybrid immunity)
245	compared to those who remain unvaccinated, given that binding IgG and NAb responses during
246	and after severe disease are higher functioning and longer lasting than when symptoms are mild
247	(28-30). Future research may also look at the relationships between viral variants and population-
248	wide antibody profiles in vaccinated and unvaccinated cohorts, as well as how antibody
249	characteristics connect to clinical outcomes and transmissibility in each group. Moreover,
250	additional focus should be paid to hybrid immunity and the impact of repeated (or breakthrough)
251	infections and boosters, including extended follow-up (8, 20) for antibody durability and titer
252	beyond one year from each type of exposure in the general population. Flexible study designs
253	that can more easily accommodate adjustments made in response to a rapidly changing viral
254	variant landscape would help future studies maintain relevance over time as SARS-CoV-2
255	transitions from pandemic to endemic circulation.
256	

Limitations

258 The data for Arm 1 are cross-sectional, therefore individual rates of seroreversion could not be 259 evaluated in direct comparison to Arm 2. Additionally, limited sample sizes at later time 260 intervals reduced statistical confidence in some time-specific point estimates of seropositivity, 261 and limited cases with confirmed hybrid immunity prevented us from evaluating those 262 individuals as a separate group. Furthermore, this study relied on self-reported infection and 263 vaccination history, and only took confirmed exposures (those that resulted in a positive 264 diagnostic test) into account. There is a high likelihood that additional exposures to SARS-CoV-265 2 went undetected and were not reflected in the self-reported COVID-19 diagnostic data; 266 however, we expect that such events would have inflated serology values most frequently in the 267 unvaccinated group. As such, these findings give a conservative estimate of the differences 268 between vaccination and natural infection in terms of antibody response. Finally, our study 269 largely coincided with circulation of the Delta variant, and reflected immune responses triggered 270 by exposure to Alpha, Beta, or Delta variants in previously-infected individuals. The Omicron 271 (BA.1) variant was discovered as this study concluded and has exhibited greater transmissibility 272 than previous variants due to a highly mutated spike protein and consequent immune evasion and 273 increased receptor affinity (31). Subsequent sublineages (BA.1.1, BA.2, BA.3, BA.4, and BA.5) 274 have since been identified and show similar or greater transmissibility and evasion of antibodies 275 compared to the parent variant (32, 33). Furthermore, a new vaccine formulation that offers more 276 protection against Omicron has been made available as a booster dose. It is uncertain how 277 combinations of variant/subvariant exposures and primary/booster vaccine formulations may 278 affect immune responses acquired through natural infection, vaccination, or hybrid exposure in a 279 rapidly shifting landscape that continues to challenge the pace of science.

280

281 Conclusions

282	This study was one of the first to directly compare population-level antibody durability acquired
283	through vaccination or natural infection in a nationwide sample and supports the conclusion that
284	completing the primary series of vaccination triggers a more durable and protective antibody
285	response compared to a known single infection with early variants of SARS-CoV-2. This study
286	further supports the importance of broad vaccination campaigns over relying upon natural,
287	infection-driven herd immunity alone in the fight against SARS-CoV-2. Future work
288	investigating antibody profiles resultant to booster doses, hybrid immunity, as well as repeat and
289	variant specific infections are critical in our continued understanding of SARS-CoV-2 and
290	COVID-19.
291	
292	Abbreviations
293	COVID-19: Coronavirus Disease 2019
294	DBS: dried blood spot
295	IgG: Immunoglobulin G
296	IQR: Interquartile range
297	NAb: Neutralizing antibody
298	NT50: NAb titers at 50% inhibition
299	US: United States
300	WHO: World Health Organization
301	
302	Declarations
303	Ethics approval and consent to participate

- 304 This protocol was approved by WCG IRB (IRB registration #20210763). All participants
- 305 provided written informed consent prior to enrollment in the study.
- 306
- 307 *Consent for publication*
- 308 Not applicable.
- 309
- 310 Availability of data and materials
- 311 The datasets used and/or analyzed during the current study are available from the corresponding
- 312 author on reasonable request.
- 313
- 314 *Competing interests*
- 315 Kaylan Olds, Devon Humphreys, Kathleen Gavin, and Timothy Bauer are full time employees of
- 316 Everly Health, Inc. Anne Wylie has no conflicts to report.
- 317
- 318 Funding
- 319 This study was funded and conducted by Everly Health, Inc.
- 320
- 321 Authors' contributions

322 KMO: Had a role in study conception, data interpretation, and drafted the work, DPH: Had a role

in study conception, performed data analysis and interpretation, and assisted in drafting the work,

324 KMG: Performed data interpretation and assisted in drafting the work, ALW: Had a role in data

analysis, data interpretation, and assisted in drafting the work, TAB: Led study conception, data

326 interpretation, and assisted in drafting the work. All authors have reviewed and

327 approved this submitted version of the manuscript.

328

- 329 Acknowledgements
- 330 The authors thank PerkinElmer Genomics, Inc. and SpearBio, Inc. for providing in-kind support
- 331 with serology testing.
- 332

333 References

- 1. Iboi EA, Ngonghala CN, Gumel AB. Will an imperfect vaccine curtail the COVID-19
- pandemic in the U.S.? Infect Dis Model. 2020;5:510-24.
- 336 2. Shah SMA, Rasheed T, Rizwan K, Bilal M, Iqbal HMN, Rasool N, et al. Risk
- 337 management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. J Infect
- 338 Public Health. 2021;14(3):331-46.
- 339 3. Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang B, et al. Factors
- 340 Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. JAMA Netw
- 341 Open. 2020;3(10):e2025594.
- Ball P. Anti-vaccine movement could undermine efforts to end coronavirus pandemic,
 researchers warn. Nature. 2020;581(7808):251.
- 5. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. National Trends
 in the US Public's Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020.
 JAMA. 2020.
- 347 6. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al.
- 348 Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med.
- 349 2022;386(23):2201-12.

- 350 7. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al.
- 351 Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in
- 352 England. Nat Commun. 2021;12(1):7217.
- 8. Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous
- 354 SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
- 355 Lancet. 2021;397(10280):1178-81.
- 356 9. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al.
- 357 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell.
- 358 2021;184(23):5699-714.e11.
- 359 10. McDade TW, Sancilio A, D'Aquila R, Mustanski B, Vaught LA, Reiser NL, et al. Low
- 360 Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory
- 361 Syndrome Coronavirus 2 in a Community-Based Serological Study. Open Forum Infect Dis.
- 362 2022;9(3):ofac055.
- 363 11. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based
- analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.
- 365 EClinicalMedicine. 2021;36:100902.
- 12. Decru B, Van Elslande J, Steels S, Van Pottelbergh G, Godderis L, Van Holm B, et al.
- 367 IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10
- 368 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare
- 369 Workers. Front Immunol. 2022;13:909910.
- 370 13. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of
- antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months
- 372 after infection. Nat Microbiol. 2022;7(3):423-33.

373	14.	Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al.			
374	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature.				
375	2021;595(7867):426-31.				
376	15.	Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et al.			
377	Model	ing of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat			
378	Comm	un. 2022;13(1):1614.			
379	16.	Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.			
380	Neutra	lizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a			
381	Fisher	Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020;58(11).			
382	17.	Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.			
383	Neutra	lizing antibody levels are highly predictive of immune protection from symptomatic			
384	SARS-	CoV-2 infection. Nat Med. 2021;27(7):1205-11.			
385	18.	Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.			
386	Antibo	dy Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J			
387	Med. 2	.021;384(6):533-40.			
388	19.	Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of			
389	Infecti	on-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.			
390	MMW	R Morb Mortal Wkly Rep. 2022;71(17):606-8.			
391	20.	Arkell P, Gusmao C, Sheridan SL, Tanesi MY, Gomes N, Oakley T, et al. Serological			
392	surveil	lance of healthcare workers to evaluate natural infection- and vaccine-derived immunity			
393	to SAF	RS-CoV-2 during an outbreak in Dili, Timor-Leste. Int J Infect Dis. 2022;119:80-6.			

394	21.	Batchi-Bouyou AL, Djontu JC, Vouvoungui JC, Mfoutou Mapanguy CC, Lobaloba

- 395 Ingoba L, Mougany JS, et al. Assessment of neutralizing antibody responses after natural SARS-
- 396 CoV-2 infection and vaccination in congolese individuals. BMC Infect Dis. 2022;22(1):610.
- 397 22. Bonura F, Genovese D, Amodio E, Calamusa G, Sanfilippo GL, Cacioppo F, et al.
- 398 Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior
- 399 Infection or mRNA BNT162b2 Vaccination. Vaccines (Basel). 2022;10(6).
- 400 23. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al.
- 401 Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J
- 402 Med. 2022;387(1):21-34.
- 403 24. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, et al. SARS-CoV-2

404 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough

405 Infections: a Retrospective Cohort Study. Clin Infect Dis. 2022.

- 406 25. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An
- 407 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome
- 408 Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by

409 Antibody and Vaccination Status. Clin Infect Dis. 2022;74(7):1208-19.

410 26. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-

411 CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-


- 412 20.
- 413 27. Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma
- therapy for the treatment of patients with COVID-19: Assessment of methods available for
- 415 antibody detection and their correlation with neutralising antibody levels. Transfus Med.
- 416 2021;31(3):167-75.


417	28.	Legros V. Denolly S.	Vogrig M. Boson B	. Siret E. Rigaill J	, et al. A longitudinal study	v of
	20.	Legios , Denony B,	105115111, 0000110	, once in, rugain s	, et al. 11 longitualitat braa	, 01

- 418 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
- 419 COVID-19 severity. Cell Mol Immunol. 2021;18(2):318-27.
- 420 29. Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
- 421 Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute
- 422 Respiratory Syndrome Coronavirus 2 Infections. J Infect Dis. 2020;222(8):1265-9.
- 423 30. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer
- 424 M, et al. Antibody response to SARS-CoV-2 for more than one year kinetics and persistence of
- 425 detection are predominantly determined by avidity progression and test design. J Clin Virol.
- 426 2022;146:105052.
- 427 31. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al.
- 428 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science.
- 429 2022;375(6583):864-8.
- 430 32. Maxmen A. Why call it BA.2.12.1? A guide to the tangled Omicron family. Nature.
 431 2022;606(7914):446-7.
- 432 33. Yao L, Zhu KL, Jiang XL, Wang XJ, Zhan BD, Gao HX, et al. Omicron subvariants
- 433 escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect Dis.
- 434 2022;22(8):1116-7.
- 435
- 436
- 437
- 438
- 439

440 Figures

- 441 Figure 1. Anti-S1 seropositivity in unvaccinated/naturally infected (Arm 1) and vaccinated (Arm
- 442 2) groups





447 Figure 2. NAb titer in unvaccinated/naturally infected (Arm 1) and vaccinated (Arm 2) groups